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Summary 
 
Objective: Guidelines on the clinical use of growth hormone therapy in adults 
adults were issued by the UK National Institute for Clinical Excellence (NICE) in 
August 2003. We conducted a retrospective clinical audit on the use of growth 
hormone (GH) in Scotland to evaluate the use of these guidelines and their 
impact on clinical practice. The audit had 2 phases. In Phase I, the impact of 
NICE criteria on specialist endocrine practice in starting and continuing GH 
replacement was assessed.  In Phase II, the reasons why some adults in 
Scotland with growth hormone deficiency were not on replacement therapy 
were evaluated. 
 
Methods: A retrospective cross-sectional case note review was carried out of 
all adult patients being followed up for growth hormone deficiency during the 
study period (1st March 2005 to 31st March 2008).  Phase I of the audit 
included 208 patients and Phase II 108 patients. 
 
Results: Sellar tumours were the main cause of GH deficiency in both phases 
of the audit. In Phase I, fifty-three patients (77%) had an AGHDA-QoL score 
>11 documented before commencing GH post-NICE guidance, compared with 
35 (25%) pre-NICE guidance. Overall, only 39 patients (18%) met the full NICE 
criteria for starting and continuing GH (pre-NICE, 11%; post-NICE, 35%).  
Phase II indicated that the main reasons for not starting GH included perceived 
satisfactory quality of life (n=47, 43%), patient reluctance (16,15%) or a medical 
contraindication (16,15%). 
 Conclusions: Although the use of quality of life assessments has increased 
following publication of the NICE guidelines, most adults on GH in Scotland did 
not fulfill the complete set of NICE criteria. The main reason for not starting GH 
therapy in adult GH-deficient patients was perceived satisfactory quality of life. 
Introduction 
Since recombinant growth hormone (GH) became available in 1985, there has 
been considerable debate regarding its use and cost-effectiveness in adults 
with growth hormone deficiency (AGHD). In 2001, the United Kingdom National 
Institute for Clinical Effectiveness (NICE) appraised the clinical effectiveness 
and cost-effectiveness of GH and Bryant et al carried out a Health Technology 
Assessment for NICE 1. However, economic modeling was limited by the lack 
of availability of a suitable cost-effectiveness measure. Sensitivity analyses 
showed the overall cost of GH therapy in adults was sensitive to GH dose, GH 
pricing and length of treatment. GH replacement in adults using an average 
maintenance dose was estimated to cost £3420 annually. The initial conclusion 
of the appraisal committee was that effectiveness was unproven but, following 
challenge by patient groups and clinicians, NICE subsequently published 
guidelines for the use of growth hormone in AGHD 2 (Appendix 1). 
 
There are five major areas of recommendation in the NICE guidance: (1) 
biochemical for diagnosing severe growth hormone deficiency, quality of life 
inclusion criterion for starting therapy  (2) biochemical and quality of life criteria 
for response to growth hormone therapy, (3) criteria for continuing replacement 
in children on replacement who have completed linear growth, (4) 
recommendations on who should initiate GH therapy, and (5) the need for a 
shared care protocol if maintenance therapy is monitored in primary care.   The 
criteria place particular emphasis on the use of the condition-specific quality of 
life tool, Assessment of Growth Hormone Deficiency in Adults, Quality of Life 
(AGHDA-QoL)3. 
 In order to evaluate the impact of these guidelines on routine clinical practice, 
an audit group was set up under the auspices of the Society for Endocrinology 
with the primary objective of assessing the impact of the NICE criteria on the 
prescribing of GH in AGHD by endocrinologists in Scotland.  
 
The purpose of the audit was to ascertain how many of the patients currently on 
GH therapy in Scotland satisfy the NICE criteria and whether the publication of 
the NICE guidance has had impact on clinical practice. The aim of Phase II was 
to ascertain the reasons why some patients with AGHD were not started on GH 
replacement. Though the NICE guidance stated that all NHS patients who were 
on therapy at the time of publication should have the option to continue 
treatment until they and their consultant consider it is appropriate to stop, we  
felt it would be useful to use them as a comparator group to assess change in 
practice. 
 
Methods 
The audit was coordinated by a Steering Group which comprised consultant 
endocrinologists from the main Scottish endocrine units. All endocrinologists in 
Scotland were surveyed at the outset, in order to identify centres using GH 
therapy in AGHD.  
 
Phase I 
Patients commenced on GH before March 2008 and under specialist review 
were identified by centre and their case notes were retrieved. The case notes 
were reviewed by endocrine specialist teams based at five main centres and 
data were collected from the case-notes of their own and neighbouring smaller 
centres. A research nurse (MC) coordinated data collection in the various 
centres. Anonymised details of each patient were entered into a research 
database. Members of the Steering Group provided local assistance in the 
interpretation of data where required.  Data were collected on GHD aetiology, 
demographic information, other pituitary hormone deficiencies, hormone 
replacement therapies, vascular risk factors and measures of treatment 
efficacy. 
 
Two hundred and thirty patients were identified for potential inclusion in the 
audit. However, only 208 patients had adequate information regarding initial 
assessment and the indications for starting GH therapy (figure 1).  Patients on 
GH replacement were divided into two groups. Group A (Pre-NICE, 139 
patients) comprised patients who were started on GH before August 2003 and 
Group B (Post NICE, 69 patients) comprised patients started after the NICE 
guidelines were published in August 2003.  
   
Phase II  
Patients with growth hormone deficiency not currently on GH replacement were 
identified. 117 patients were identified for potential inclusion in the audit. 
However, on detailed evaluation, only 108 patients were confirmed to have GH 
deficiency and included in the study (figure 1).  
 
Audit Standards 
I. Patients should meet the biochemical criteria for severe GH deficiency. 
II. Patients should meet AGHDA-QoL criteria for severe GH deficiency. 
III. All patients should have first been assessed for other hormone 
deficiencies and optimally replaced. 
IV. All patients on long term GH replacement should meet the AGHDA-QoL 
improvement criteria after starting GH therapy and have achieved optimal dose 
titration. 
 
Results 
 
Phase 1 
Of 208 patients included, 106 were female (51%). The mean age at diagnosis 
of the primary cause of GH deficiency was 32 years (SD 16). Mean age at the 
start of GH therapy was 41 years (SD 14, Range 10-76). The majority of 
patients were Caucasian (193, 93%); ethnicity information was not available in 
10 patients. 
Sixty-nine patients (41%) were started on GH after the NICE criteria were 
published (Group B). Occupational details were available in 167 patients (80%); 
professional (n=58, 28%), manual skilled (36, 17%), non-manual skilled (16, 
8%), partly skilled (12, 6%), managerial (4, 2%), unemployed (14, 7%), 
unskilled (27,12%).  
 
The causes of GH deficiency are shown in Table 1: sella tumours were the 
commonest cause (137, 66%). Vascular risk factors and co-morbidities in the 
study population were hypertension (45, 21.6%), hyperlipidaemia (30, 14.4%), 
diabetes mellitus (14, 6.2%), stroke (10, 4.8%), ischaemic heart disease (8, 
3.8%) and peripheral vascular disease (1, 0.5%). 
 
Audit Standard 1. Biochemical diagnosis of Growth Hormone deficiency 
187 patients had a dynamic GH stimulation test. Of these 183 patients (89%) 
the dynamic GH stimulation test performed confirmed severe GH deficiency  (< 
9 mu/l on Insulin Tolerance Test , < 27 mu/l on GHRH + Arginine testing, < 17 
mu/l on Arginine testing). The most commonly used test was insulin-induced 
hypoglycaemia. 122 patients (89%) in Group A met this criterion, compared to 
61 patients (88.4%) in Group B. Four patients had a partial GH deficiency (peak 
GH levels between 9 and 15 mu/l). Twenty one patients did not have any 
dynamic tests performed and were diagnosed on the basis of low age-related 
IGF-1 levels and more than 2 baseline pituitary hormone deficiencies.    8 
patients had isolated GH deficiency.   Only one patient with isolated GH 
deficiency had 2 different dynamic tests for GH secretion. 
 
Audit Standard 2. Assessment of AGHDA-QoL  
The median AGHDA-QoL for patients in phase 1 was 17 (IQR 9). There was a 
significant increase in the proportion of patients who had a formal QoL 
assessment, from 51 patients (37%) in group A to 60 patients (87%) in group B 
(P<0.001, Fig. 2).  Nevertheless, 12 patients in Group A and 6 patients in 
Group B who had AGHDA-QoL scores below 11 were started on GH therapy 
(10.8% of all patients). In the six patients in Group B, three had previously been 
on GH therapy and had noticed a significant deterioration in quality of life. The 
remaining three had AGHDA-QOL scores close to 11 (range 8-10) and the 
consultant felt that a trial of GH therapy would be justified. In group A  7 
patients were perceived to  have  a poor quality of life,  5 patient  had a low 
bone mineral density. 
 
Audit Standard 3. Assessment of other pituitary hormone deficiencies 
All patients (100%) had appropriate baseline pituitary function testing. Most 
patients were taking other pituitary hormone replacements; thyroxine 83%, 
hydrocortisone 79%, testosterone 70% of men, oestrogens 46% of women and 
desmopressin 25%. Baseline AGHDA was obtained after optimal replacement 
of other pituitary deficiencies. 
 
Audit Standard 4. Improvement in AGHDA-QoL. 
The median fall in AGHDA-QOL was 6 points( IQR 10, Range 0-25). Forty-five 
patients (32%) in Group A and 52 patients (75.4%) in Group B had a recorded 
AGHDA-QoL before and after starting GH (Fig. 3). In group A, 17 patients 
(12%) satisfied the AGHDA improvement criteria while, for 28 patients (41%) in 
Group B, the AGHDA score improved by 7 points or more.   
In group B, 24 patients had a less than 7 point change in AGHDA-QOL and 
were continued on growth hormone therapy despite the desired lack of 
improvement in AGHDA-QoL. Of these five had an initial AGHDA of greater 
than 20 and one had an AGDHA of 25. Sixteen of the 24 patients in group B, 
who did not meet audit standard 4, showed a lesser improvement in AGHDA-
QOL and a clinical comment in the notes stating an improvement in quality of 
life since starting growth hormone therapy. 
 
The median time between baseline and repeat estimation of AGHDA was 10 
months (interquartile range 6 months). The median dose of growth hormone 
used was 0.5 mgs (interquartile range 0.2mgs) 
 
Twenty six patients (38%) met all the NICE standards (38%) in Group B.  Only 
15 (11%) in Group A would have met the current criteria.  There was a variation 
in the use of AGHDA-QoL among the centres and one of the major centres did 
not use AGHDA-QoL at all. If data from this centre are excluded, the overall 
proportion of patients meeting the AGHDA-QoL criteria increased from 12% to 
44% (Fig. 4).  
There is a significant variation in the pattern of Growth hormone prescribing 
within Scotland. Only 2 of the 5 centres prescribed Growth hormone therapy in 
significant numbers following the NICE guidance and both centres showed an 
improvement in adherence to the NICE criteria. There was significant fall in 
numbers started on Growth hormone in Centre B as it was involved in trial of 
Growth hormone therapy prior to 2003 and hence most of the candidates 
suitable for growth hormone therapy were already considered for the same.  
 
Phase II 
There were 108 patients with a diagnosis of GHD who were not taking GH; 54 
(50%) were female. Details regarding occupation were available in 83 patients 
(Managerial 3, 3%; Professional 15, 14%; Manual Skilled 18, 17%; Non-manual 
Skilled 9, 8%; Partly skilled 8, 7%; Unemployed 10, 9%; Unskilled 20, 19%; Not 
recorded 25, 23%).   
 
The mean age at diagnosis of the primary cause of GH deficiency was 46.2 
years (SD 21.8). The mean age at the time of the study was 57.9 years (SD 
17.4). The co-existing vascular risk factors in the study population were 
hypertension (39, 36.1%), hyperlipidaemia (32, 29.6%), diabetes mellitus (8, 
7.3%), stroke (11, 10.0%), ischaemic heart disease (17, 15.4%) and peripheral 
vascular disease (2, 1.8%).  
 
Most patients were on other pituitary hormone replacement therapies; 
hydrocortisone 79 (73.1%), thyroxine 81 (75%), testosterone 49 (91% of men) 
oestrogen 39 (72% of women) and desmopressin 21 (19.4%). Fifty-four 
patients had a low IGF-1 but no dynamic tests to confirm GH deficiency.  Forty-
eight of 54 patients who had a dynamic test had a GH peak lower than 9.0 mU/l 
(mean peak GH level 5.6 mU/L, SD 11.8). Table 2 lists the reasons why 
patients were not on GH therapy. Table 3 compares the characteristic of the 
patients in the two phases of the audit. 
 
Discussion 
The Society for Endocrinology estimates the prevalence of adult-onset GH 
deficiency is approximately 1 in 10,000 of the UK adult population and if adults 
with childhood-onset GH deficiency are also considered, the prevalence may 
be as high as 3 in 10,000. Based on the 2001 census, this would imply there 
should be around 1200 patients with GH deficiency in Scotland. We identified 
208 patients on GH therapy and another 108 untreated with GHD in Scotland, 
which represents approximately 25% of the individuals who might be expected 
to have GHD.  Although it is likely a small number of patients on GH therapy 
will have been missed in the survey and others will have declined the offer of 
GH, it seems probable that many patients who may benefit from GH 
replacement are not being considered.  This may reflect concerns about costs 
of treatment and the clinical practice of specialists involved in patient care.  
While it is possible we missed patients who were not being followed in 
specialist centres, all patients included in this audit were managed by a 
consultant endocrinologist with an interest in pituitary disease.  Few patients in 
Scotland with pituitary disease are cared for by non-endocrinologists. Patient 
on Growth hormone therapy were diagnosed with their primary condtion at a 
younger age and there was also greater proportion of managerial and 
professional individuals in this group (table 3). 
 
The present data suggest that adherence to guidelines for the use of GH in 
adult patients has improved following NICE guidance in two of the Scottish 
centres (A and D), but remains suboptimal in the other centres. In centre B all 
relevant patients had been actively recruited as part of a clinical trial before 
2003 and therefore there was a relative fall in the number of patients started on 
growth hormone between 2003 and 2006.  The overall compliance rate with all 
NICE criteria increased from 11% to 38% with greater use of AGHDA-QoL after 
the NICE criteria were published; this was the case in all centres.  Indeed, 
although most patients now meet the criteria for initiation of therapy, the 
commonest reason for not meeting the NICE criteria is a failure to achieve the 
required improvement in AGHDA-QoL.  This suggests clinicians and patients 
are keen to continue therapy despite the AGHDA score not improving by at 
least 7 points.  Our impression is that many patients request continuation of 
therapy as they feel subjectively better on GH, even though this has not been 
corroborated by an improved AGHDA-QoL score. This suggests a 7-point 
improvement in AGHDA-QoL may be an inappropriate criterion and worthy of 
review. Indeed, the use of AGHDA-QoL to assess quality in life has been 
controversial, with one study showing that it could not discriminate between 
extremes of GH output and thus having limited ability to detect improvement in 
quality of life during GH replacement 4. Normative data for AGHDA-QoL are 
available in a UK cohort; in all age groups there were statistically higher scores 
AGHDA-QoL scores in GHD patients  5.  However patients with adult-onset 
GHD on GH replacement had mean AGHDA-QOL scores of 12.6 in men (SD 
6.6) and 15.1 in women (SD 6.3) demonstrating that the range of AGHDA 
scores for the patients on treatment in this cohort would fall outside NICE 
Guidelines. Finally, in a study of the KIMS database there was a decrease in 
mean AGHDA score of 2.2 points at 6 months and 2.8 points at 12 months in 
men; in women a mean decrease of 2.8 and 4.8 points at 6 and 12 months was 
seen 6. Again, these changes would not meet the pre-specified NICE criteria, 
but may suggest that patients started on GH may still achieve clinical 
improvement that is not reflected in this rather arbitrary end point and the 
thresholds for baseline values and incremental change expected may need to 
reconsidered based on observed change in prospective cohorts 7.  
 
Of the centres surveyed, three had a formal shared care protocol, and one had 
developed an informal approach which had been in successful use for over 12 
years. However, we believe that a formal protocol can offer a robust 
mechanism that ensure support for prescribing in primary care and should be 
seen as the most appropriate way of managing GH replacement. 
 
The main reason for not starting GH therapy in our cohort of patients was a 
perceived normal quality of life (43.5%). However only half these patients were 
formally assessed using a formal AGHDA-QoL. However, it is possible that 
some of these patients may not have been assessed with an AGHDA 
questionnaire or with dynamic tests because they had indicated that they had 
made a clear decision not to have a trial of GH therapy. More data are required 
about the potential benefits of GH replacement beyond those of improved 
quality of life before such patients should be given greater encouragement to 
initiate GH.  Thus, while it is possible that many patients may miss possible 
long term benefits, such as improved bone density and cardiovascular health, 
lack of firm end-point data makes this speculative at present.  
 
The Scottish Medicines consortium states that ‘patients must have growth 
hormone deficiency as a result of hypothalamic or pituitary disease and at least 
one other hormone deficiency diagnosed (except for prolactin) and adequate 
replacement therapy instituted, before replacement therapy using growth 
hormone may begin’. Healthcare Improvement Scotland issue alerts to notify 
NHS Scotland of the publication of NICE Guidance and advises on its 
applicability to Scotland. However this mechanism was only started in April 
2011. Therefore part of the reason for the reduced adherence to the NICE 
guidance may be that the AGHDA-QOl criteria is not considered important for 
funding treatment by the Scottish health boards. 
 
 
 
 
 
In summary, this study has shown that, even in centres with a specialist 
endocrinology interest, the implementation of NICE Guidelines on GH 
replacement in adults remains incomplete. This may reflect individual specialist 
interpretation of the Guidelines, and pragmatic decision-making in consultation 
with patients. In particular, the AGHDA-QoL score criteria were not fully 
implemented, calling their actual validity into question. Finally, it is clear that a 
substantial proportion of patients who might qualify for GH replacement do not 
receive this, reflecting a mixture of patient choice, clinical reasoning and, 
possibly, failure by clinicians to offer therapy.  We have presented the results of 
the audit at regional and national endocrine professional conferences. We plan 
to develop a simple paper based audit tool based on the NICE criteria to act as 
a prompt and to re-audit the use of growth hormone in the 4 major centres in 
2015. 
 
The limitations of the study were its retrospective nature and the incomplete 
retrieval of information for some patients who had part of their management 
outside their current centre of follow up.  The strengths are that this was a 
national survey, in a relatively static population, of actual management in daily 
clinical practice. 
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Tables and Figures 
Table 1: Causes of GH deficiency  
Cause of GH deficiency Phase I Phase II 
No of patients % No of patients % 
Sellar tumour 137 65.9 71 65.8 
Post-radiotherapy for 
haematological 
malignancies 
12 5.8   
Post-radiotherapy for non-
sellar brain tumours 
12 5.8   
Sheehan’s syndrome 7 3.4 4 3.7 
Head trauma 3 1.4 2 1.9 
Autoimmune 2 1.0 3 2.8 
Non-sellar brain tumour 2 1.0   
Other 33 15.9 28 25.9 
 
Table 2: Reasons for patients not being on GH replacement therapy 
Reason Number (%) 
 AGHDA-QOL score <11 22 (20.4%) 
Normal QOL (clinical judgement) 25 (23.1%) 
GH replacement not considered 12 (11.1%) 
Other medical  reason 
(e.g malignancy, respiratory failure, 
stroke*) 
16 (14.8%) 
Patient unwilling 16 (14.8%) 
Planning pregnancy 2 (1.9%) 
Previously tried and stopped GH - no 
QOL change 
2 (1.9%) 
Previously tried and stopped GH - side 
effects 
1 (0.9%) 
Optimising other pituitary hormone 
replacements before considering GH  
6 (4.6%) 
Age (range 78- 86 yrs)  6 (5.6%) 
 
(*eg occipitoparietal meningioma, Sigmoid adenocarcinoma, Cerebellar Stroke, 
Severe Chronic Obstructive airway disease, Metastatic prostate cancer, severe 
osteoarthritis) 
 
 
Table 3: Comparison of characteristics of patients GH-treated (phase 1) and 
non GH-treated groups (phase 2) 
Patient Characteristic 
 
Phase 1 
GH-treated 
n=208 
Phase 2 
Non GH-treated 
n=108  
 
 
P-value 
Gender  
Women 
 
106 (50.9%) 
 
54 (50% 
 
NS 
Mean age  
(at diagnosis of the primary cause of 
GH deficiency) 
32 years (SD 16) 46.2 (SD 21.8) P<0.001 
Occupations 
Group 1 ( Managerial, Professional) 
 
Group 2 ( Manual Skilled, non manual 
Skilled, partly skilled) 
 
Group 3 (Unemployed,Unskilled) 
 
Unknown 
 
58 (27.9%) 
 
50 (24.0%) 
 
 
40 (19.2%) 
 
60 (28.8%) 
 
15 (13.9%) 
 
26 (24.1%) 
 
 
30 (27.8%) 
 
37 (34.3%) 
 
P=0.02 
Ethinicity 
Caucausian  
 
193 (92.8%) 
 
106 (98.1%) 
 
NS 
    NS : not significant 
Figure 1 Outline of patients included in the 2 phases of the Growth Hormone 
audit 
 
 
Figure 2:  Assessment of AGHDA QOL 
 
  
Figure 3. Improvement in AGHDA-QOL 
 
 
 
Figure 4: Patients satisfying all NICE criteria in the 5 main centres.  
 
